A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891).Kunle Odunsi, Rafael G. Amado, Oliver Dorigo et al.|Journal of Clinical Oncology|2017Cited by 10